Ursodeoxycholic acid therapy in primary biliary cirrhosis. 1996

M Podda, and A Crosignani, and P M Battezzati, and M Quagliuolo, and C Valsania, and P Invernizzi, and M Zuin
Cattedra di Medicina Interna, Università di Milano, Italy.

A review is made of the literature regarding the present status of ursodeoxycholic acid in the treatment of primary biliary cirrhosis, focusing on the difficulties encountered in establishing the efficacy of this and any other therapy in the management of the disease. It is concluded that further studies or, at least, an updated meta-analysis including the final data emerging from the multicentre, long-term, randomised, double-blind, controlled trials currently under way are needed to establish the clinical importance of ursodeoxycholic acid as a therapeutic agent in primary biliary cirrhosis.

UI MeSH Term Description Entries
D008105 Liver Cirrhosis, Biliary FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cholangitis involves the destruction of small intra-hepatic bile ducts and decreased bile secretion. Secondary biliary cholangitis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes. Biliary Cirrhosis,Biliary Cirrhosis, Primary,Biliary Cirrhosis, Secondary,Cholangitis, Chronic Nonsuppurative Destructive,Liver Cirrhosis, Obstructive,Primary Biliary Cholangitis,Biliary Cirrhosis, Primary, 1,Primary Biliary Cirrhosis,Secondary Biliary Cholangitis,Secondary Biliary Cirrhosis,Biliary Cholangitides, Primary,Biliary Cholangitis, Primary,Biliary Cholangitis, Secondary,Cholangitides, Primary Biliary,Cholangitis, Primary Biliary,Cholangitis, Secondary Biliary,Cirrhosis, Biliary,Cirrhosis, Secondary Biliary,Liver Cirrhoses, Biliary,Obstructive Liver Cirrhosis,Primary Biliary Cholangitides,Secondary Biliary Cholangitides
D005765 Gastrointestinal Agents Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. Digestants,Gastric Agents,Gastric Drugs,Gastrointestinal Drugs,Agents, Gastric,Agents, Gastrointestinal,Drugs, Gastric,Drugs, Gastrointestinal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014580 Ursodeoxycholic Acid An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic. Deoxyursocholic Acid,3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid,Cholit-Ursan,Cholofalk,Delursan,Destolit,Sodium Ursodeoxycholate,Urdox,Ursacholic Acid,Urso,Urso Heumann,Ursobilane,Ursochol,Ursodiol,Ursofalk,Ursogal,Ursolite,Ursolvan,3 alpha,7 beta Dihydroxy 5 beta cholan 24 oic Acid,Acid, Deoxyursocholic,Acid, Ursacholic,Acid, Ursodeoxycholic,Ursodeoxycholate, Sodium
D015337 Multicenter Studies as Topic Works about controlled studies which are planned and carried out by several cooperating institutions to assess certain variables and outcomes in specific patient populations, for example, a multicenter study of congenital anomalies in children. Multicenter Trials,Multicentre Studies as Topic,Multicentre Trials,Multicenter Trial,Multicentre Trial,Trial, Multicenter,Trial, Multicentre,Trials, Multicenter,Trials, Multicentre
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical

Related Publications

M Podda, and A Crosignani, and P M Battezzati, and M Quagliuolo, and C Valsania, and P Invernizzi, and M Zuin
May 1995, Hepatology (Baltimore, Md.),
M Podda, and A Crosignani, and P M Battezzati, and M Quagliuolo, and C Valsania, and P Invernizzi, and M Zuin
January 1994, Scandinavian journal of gastroenterology. Supplement,
M Podda, and A Crosignani, and P M Battezzati, and M Quagliuolo, and C Valsania, and P Invernizzi, and M Zuin
March 1996, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
M Podda, and A Crosignani, and P M Battezzati, and M Quagliuolo, and C Valsania, and P Invernizzi, and M Zuin
October 1993, Zeitschrift fur Gastroenterologie,
M Podda, and A Crosignani, and P M Battezzati, and M Quagliuolo, and C Valsania, and P Invernizzi, and M Zuin
April 1989, Lancet (London, England),
M Podda, and A Crosignani, and P M Battezzati, and M Quagliuolo, and C Valsania, and P Invernizzi, and M Zuin
May 1997, Seminars in liver disease,
M Podda, and A Crosignani, and P M Battezzati, and M Quagliuolo, and C Valsania, and P Invernizzi, and M Zuin
September 1993, Orvosi hetilap,
M Podda, and A Crosignani, and P M Battezzati, and M Quagliuolo, and C Valsania, and P Invernizzi, and M Zuin
April 1992, Gastroenterology,
M Podda, and A Crosignani, and P M Battezzati, and M Quagliuolo, and C Valsania, and P Invernizzi, and M Zuin
August 1994, Gastroenterology,
M Podda, and A Crosignani, and P M Battezzati, and M Quagliuolo, and C Valsania, and P Invernizzi, and M Zuin
January 1994, BMJ (Clinical research ed.),
Copied contents to your clipboard!